The project has received funding from the European Union’s Horizon 2020 research and innovation
programme under grant agreement No 778277
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
Osteoporosis constitutes a major public health concern. The economic burden of osteoporotic fractures in EU is expected to increase 25% by 2025 compared to 2010. These estimates may indicate an inefficiency of current drugs for osteoporosis. Actually, the use of pharmacological agents for osteoporosis has been decreasing in EU, probably due to the reported side effects. Therefore, there is a need for innovative agents to reduce the burden of osteoporosis. The COLOSTEO project will build on the complementary expertise of research and industrial partners through knowledge sharing between sectors.
Colosteo Project Video
The COLOSTEO project came to an end, after 4 years of exploring the creation of an innovative nutraceutical product based on colostrum to prevent osteoporosis! Our findings and the conclusion of our research studies will stay available to all.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
